Lineage Cell Therapeutics, Inc. has announced the dosing of the first patient in a new clinical study evaluating OPC1 for subacute and chronic spinal cord injury. The study, known as DOSED, is assessing the safety and utility of a novel parenchymal spinal delivery system designed to deliver OPC1 directly to the site of injury. OPC1, an investigational allogeneic stem cell-derived transplant, aims to replace or support dysfunctional cells in the spinal cord to restore or enhance functional activity. This trial marks the first-ever administration of OPC1 to a patient with a chronic spinal cord injury, expanding the potential treatable population for this therapy. No results from the study have been presented yet; the trial is ongoing with plans to enroll additional patients and gather functional assessments to explore efficacy signals.